<p>Tandem Diabetes Care（納斯達克代碼：TNDM - 獲取免費報告）在週六發佈給客户和投資者的研究報告中，被華爾街 Zen 的股票研究人員從 “賣出” 評級上調至 “持有” 評級。</p>
<p>獲取 <strong>Tandem Diabetes Care</strong> 的提醒：</p>
<p>其他股票研究分析師最近也發佈了關於該公司的研究報告。瑞銀集團將 Tandem Diabetes Care 的目標價從 20.00 美元下調至 17.00 美元，並在 8 月 7 日的報告中對該股票給予 “中性” 評級。派珀·桑德勒將 Tandem Diabetes Care 的評級從 “增持” 下調至 “中性”，並在 8 月 7 日的研究報告中將該公司的目標價從 30.00 美元下調至 14.00 美元。巴克萊將 Tandem Diabetes Care 的目標價從 53.00 美元下調至 51.00 美元，並在 8 月 8 日的研究報告中對該公司給予 “增持” 評級。富國銀行將 Tandem Diabetes Care 的目標價從 20.00 美元下調至 13.00 美元，並在 8 月 7 日的研究報告中對該公司給予 “等權重” 評級。最後，加拿大皇家銀行在 9 月 29 日的研究報告中重申了 “買入” 評級，並對 Tandem Diabetes Care 的股票設定了 24.00 美元的目標價。五位研究分析師對該股票給予 “買入” 評級，十一位給予 “持有” 評級，一位給予 “賣出” 評級。根據 MarketBeat.com 的數據，Tandem Diabetes Care 目前的共識評級為 “持有”，共識目標價為 22.19 美元。</p>
<p><strong>獲取我們對 Tandem Diabetes Care 的最新分析</strong></p>
<h2>Tandem Diabetes Care 股價下跌 3.3%</h2>
<p>TNDM 股票在週五開盤價為 14.79 美元。該股票的 50 日移動平均價格為 12.62 美元，200 日移動平均價格為 16.44 美元。該公司的市值為 9.9936 億美元，市盈率為-4.79，貝塔值為 1.48。Tandem Diabetes Care 的 52 周低點為 9.98 美元，52 周高點為 38.28 美元。該公司的債務與股本比率為 2.32，速動比率為 1.88，流動比率為 2.44。</p>
<p>Tandem Diabetes Care（納斯達克代碼：TNDM - 獲取免費報告）最近在 8 月 6 日發佈了其財報。這家醫療設備公司報告本季度每股收益為（0.48 美元），低於分析師的共識預期（0.40 美元）0.08 美元。該季度的營業收入為 2.4068 億美元，而分析師預期為 2.3839 億美元。Tandem Diabetes Care 的淨利潤率為-20.51%，股本回報率為-65.40%。該季度的營業收入較去年同期增長了 8.5%。在去年同期，該公司每股收益為（0.47 美元）。股票分析師預測 Tandem Diabetes Care 在本財年將發佈-1.68 美元的每股收益。</p>
<h2>Tandem Diabetes Care 的內部買賣</h2>
<p>在相關消息中，首席財務官 Leigh Vosseller 在 8 月 8 日的交易中購買了 13,720 股該股票。該股票的平均購買成本為每股 10.89 美元，總價值為 149,410.80 美元。交易完成後，首席財務官直接持有該公司 25,580 股，價值約為 278,566.20 美元。這筆交易代表了他們持股的 115.68% 的增長。該交易已在證券交易委員會的備案中披露，相關信息可在 SEC 網站上找到。此外，首席執行官 John F. Sheridan 在 8 月 11 日的交易中購買了 10,000 股該股票。該股票的平均購買成本為每股 10.23 美元，總價值為 102,300.00 美元。交易完成後，首席執行官持有該公司 106,327 股，價值為 1,087,725.21 美元。這筆交易使他們的持股增加了 10.38%。該購買的披露信息可以在這裏找到。1.90% 的股票由公司內部人士持有。</p>
<h2>機構資金流入和流出</h2>
<p>一些對沖基金和其他機構投資者最近對 TNDM 的持倉進行了調整。Assetmark Inc.在第一季度將其在 Tandem Diabetes Care 的股份增加了 42.9%。Assetmark Inc.目前持有 1,750 股該醫療設備公司的股票，價值 34,000 美元，此前在該期間內購買了 525 股。CWM LLC 在第二季度將其在 Tandem Diabetes Care 的股份增加了 262.6%。CWM LLC 目前持有 2,796 股該醫療設備公司的股票，價值 52,000 美元，此前在該期間內購買了 2,025 股。布魯克林投資集團在第一季度將其在 Tandem Diabetes Care 的股份增加了 417.8%。布魯克林投資集團目前持有 3,397 股該醫療設備公司的股票，價值 65,000 美元，此前在該期間內購買了 2,741 股。Nisa Investment Advisors LLC 在第二季度將其在 Tandem Diabetes Care 的股份增加了 186.9%。Nisa Investment Advisors LLC 目前持有 4,171 股該醫療設備公司的股票，價值 78,000 美元，此前在該期間內購買了 2,717 股。最後，懷俄明州在第一季度將其在 Tandem Diabetes Care 的股份增加了 49.1%。懷俄明州目前持有 4,467 股該醫療設備公司的股票，價值 86,000 美元，此前在該期間內購買了 1,471 股。</p>
<h2>Tandem Diabetes Care 公司簡介</h2>
<p>（獲取免費報告）</p>
<p>Tandem Diabetes Care, Inc.是一家醫療設備公司，設計、開發和商業化技術解決方案，服務於美國及國際上的糖尿病患者。該公司的旗艦產品是 t:slim X2 胰島素輸送系統，這是一個用於管理胰島素輸送並在泵的主屏幕上直接顯示連續血糖監測傳感器信息的泵平台；以及 Tandem Mobi 胰島素泵，這是一個自動胰島素輸送系統。</p>
<h2>另見</h2>
<ul>
<li>我們更看好的五隻股票，勝過 Tandem Diabetes Care</li>
<li>標普 500 指數股票向投資者傳達了什麼市場信息？</li>
<li>這家 AI 芯片巨頭可能是市場下一個大贏家</li>
<li>如何計算退休收入：MarketBeat 的計算器</li>
<li>博通與 OpenAI 達成協議：這對 AVGO 股票來説是一個巨大的勝利</li>
<li>3 只超市股票證明它們仍然是必需品</li>
<li>機構正在推動 CrowdStrike 的下一輪上漲</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VE5ETQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VE5ETQ"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資$1,000 在 Tandem Diabetes Care 嗎？</h2>
<p>在你考慮 Tandem Diabetes Care 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Tandem Diabetes Care 並不在名單上。</p>
<p>雖然 Tandem Diabetes Care 目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

TNDM

<p>華爾街禪將 Tandem Diabetes Care（納斯達克代碼：TNDM）的評級從 “賣出” 上調至 “持有”。其他分析師的意見各異，瑞銀將其目標價下調至 17 美元，派珀·桑德勒則下調至 14 美元。該股開盤價為 14.79 美元，下跌 3.3%，市值為 9.9936 億美元。公司報告每股虧損 0.48 美元，未達到預期，但收入同比增長 8.5%。內部人士購入股票，首席財務官和首席執行官均購買了股份。共識評級維持在 “持有”，目標價為 22.19 美元</p>

<p>Tandem Diabetes Care (NASDAQ:TNDM - Get Free Report) was upgraded by equities researchers at Wall Street Zen from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a research report issued to clients and investors on Saturday.</p>
<div class="lb-trans"><p>Tandem Diabetes Care（納斯達克代碼：TNDM - 獲取免費報告）在週六發佈給客户和投資者的研究報告中，被華爾街 Zen 的股票研究人員從 “賣出” 評級上調至 “持有” 評級。</p>
</div><p>Get <strong>Tandem Diabetes Care</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Tandem Diabetes Care</strong> 的提醒：</p>
</div><p>Other equities research analysts also recently issued research reports about the company. UBS Group reduced their target price on Tandem Diabetes Care from $20.00 to $17.00 and set a &#34;neutral&#34; rating on the stock in a report on Thursday, August 7th. Piper Sandler cut Tandem Diabetes Care from an &#34;overweight&#34; rating to a &#34;neutral&#34; rating and dropped their price target for the company from $30.00 to $14.00 in a research note on Thursday, August 7th. Barclays dropped their price target on Tandem Diabetes Care from $53.00 to $51.00 and set an &#34;overweight&#34; rating for the company in a research note on Friday, August 8th. Wells Fargo &amp; Company dropped their price target on Tandem Diabetes Care from $20.00 to $13.00 and set an &#34;equal weight&#34; rating for the company in a research note on Thursday, August 7th. Finally, Canaccord Genuity Group reiterated a &#34;buy&#34; rating and issued a $24.00 price target on shares of Tandem Diabetes Care in a research note on Monday, September 29th. Five research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, Tandem Diabetes Care presently has a consensus rating of &#34;Hold&#34; and a consensus price target of $22.19.</p>
<div class="lb-trans"><p>其他股票研究分析師最近也發佈了關於該公司的研究報告。瑞銀集團將 Tandem Diabetes Care 的目標價從 20.00 美元下調至 17.00 美元，並在 8 月 7 日的報告中對該股票給予 “中性” 評級。派珀·桑德勒將 Tandem Diabetes Care 的評級從 “增持” 下調至 “中性”，並在 8 月 7 日的研究報告中將該公司的目標價從 30.00 美元下調至 14.00 美元。巴克萊將 Tandem Diabetes Care 的目標價從 53.00 美元下調至 51.00 美元，並在 8 月 8 日的研究報告中對該公司給予 “增持” 評級。富國銀行將 Tandem Diabetes Care 的目標價從 20.00 美元下調至 13.00 美元，並在 8 月 7 日的研究報告中對該公司給予 “等權重” 評級。最後，加拿大皇家銀行在 9 月 29 日的研究報告中重申了 “買入” 評級，並對 Tandem Diabetes Care 的股票設定了 24.00 美元的目標價。五位研究分析師對該股票給予 “買入” 評級，十一位給予 “持有” 評級，一位給予 “賣出” 評級。根據 MarketBeat.com 的數據，Tandem Diabetes Care 目前的共識評級為 “持有”，共識目標價為 22.19 美元。</p>
</div><p><strong>Get Our Latest Analysis on Tandem Diabetes Care</strong></p>
<div class="lb-trans"><p><strong>獲取我們對 Tandem Diabetes Care 的最新分析</strong></p>
</div><h2>Tandem Diabetes Care Trading Down 3.3%</h2>
<div class="lb-trans"><h2>Tandem Diabetes Care 股價下跌 3.3%</h2>
</div><p>Shares of TNDM stock opened at $14.79 on Friday. The stock's fifty day moving average price is $12.62 and its two-hundred day moving average price is $16.44. The company has a market cap of $999.36 million, a PE ratio of -4.79 and a beta of 1.48. Tandem Diabetes Care has a fifty-two week low of $9.98 and a fifty-two week high of $38.28. The company has a debt-to-equity ratio of 2.32, a quick ratio of 1.88 and a current ratio of 2.44.</p>
<div class="lb-trans"><p>TNDM 股票在週五開盤價為 14.79 美元。該股票的 50 日移動平均價格為 12.62 美元，200 日移動平均價格為 16.44 美元。該公司的市值為 9.9936 億美元，市盈率為-4.79，貝塔值為 1.48。Tandem Diabetes Care 的 52 周低點為 9.98 美元，52 周高點為 38.28 美元。該公司的債務與股本比率為 2.32，速動比率為 1.88，流動比率為 2.44。</p>
</div><p>Tandem Diabetes Care (NASDAQ:TNDM - Get Free Report) last issued its earnings results on Wednesday, August 6th. The medical device company reported ($0.48) earnings per share for the quarter, missing analysts' consensus estimates of ($0.40) by ($0.08). The business had revenue of $240.68 million during the quarter, compared to analyst estimates of $238.39 million. Tandem Diabetes Care had a negative net margin of 20.51% and a negative return on equity of 65.40%. The company's revenue for the quarter was up 8.5% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.47) EPS. Equities analysts predict that Tandem Diabetes Care will post -1.68 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Tandem Diabetes Care（納斯達克代碼：TNDM - 獲取免費報告）最近在 8 月 6 日發佈了其財報。這家醫療設備公司報告本季度每股收益為（0.48 美元），低於分析師的共識預期（0.40 美元）0.08 美元。該季度的營業收入為 2.4068 億美元，而分析師預期為 2.3839 億美元。Tandem Diabetes Care 的淨利潤率為-20.51%，股本回報率為-65.40%。該季度的營業收入較去年同期增長了 8.5%。在去年同期，該公司每股收益為（0.47 美元）。股票分析師預測 Tandem Diabetes Care 在本財年將發佈-1.68 美元的每股收益。</p>
</div><h2>Insider Buying and Selling at Tandem Diabetes Care</h2>
<div class="lb-trans"><h2>Tandem Diabetes Care 的內部買賣</h2>
</div><p>In related news, CFO Leigh Vosseller bought 13,720 shares of the stock in a transaction that occurred on Friday, August 8th. The stock was acquired at an average cost of $10.89 per share, with a total value of $149,410.80. Following the transaction, the chief financial officer directly owned 25,580 shares in the company, valued at approximately $278,566.20. This trade represents a 115.68% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities &amp; Exchange Commission, which is available at the SEC website. Also, CEO John F. Sheridan bought 10,000 shares of the stock in a transaction that occurred on Monday, August 11th. The shares were bought at an average cost of $10.23 per share, with a total value of $102,300.00. Following the completion of the transaction, the chief executive officer owned 106,327 shares in the company, valued at $1,087,725.21. The trade was a 10.38% increase in their ownership of the stock. The disclosure for this purchase can be found here. 1.90% of the stock is owned by company insiders.</p>
<div class="lb-trans"><p>在相關消息中，首席財務官 Leigh Vosseller 在 8 月 8 日的交易中購買了 13,720 股該股票。該股票的平均購買成本為每股 10.89 美元，總價值為 149,410.80 美元。交易完成後，首席財務官直接持有該公司 25,580 股，價值約為 278,566.20 美元。這筆交易代表了他們持股的 115.68% 的增長。該交易已在證券交易委員會的備案中披露，相關信息可在 SEC 網站上找到。此外，首席執行官 John F. Sheridan 在 8 月 11 日的交易中購買了 10,000 股該股票。該股票的平均購買成本為每股 10.23 美元，總價值為 102,300.00 美元。交易完成後，首席執行官持有該公司 106,327 股，價值為 1,087,725.21 美元。這筆交易使他們的持股增加了 10.38%。該購買的披露信息可以在這裏找到。1.90% 的股票由公司內部人士持有。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>機構資金流入和流出</h2>
</div><p>A number of hedge funds and other institutional investors have recently made changes to their positions in TNDM. Assetmark Inc. lifted its stake in shares of Tandem Diabetes Care by 42.9% in the 1st quarter. Assetmark Inc. now owns 1,750 shares of the medical device company's stock valued at $34,000 after purchasing an additional 525 shares during the period. CWM LLC lifted its stake in shares of Tandem Diabetes Care by 262.6% in the 2nd quarter. CWM LLC now owns 2,796 shares of the medical device company's stock valued at $52,000 after purchasing an additional 2,025 shares during the period. Brooklyn Investment Group lifted its stake in shares of Tandem Diabetes Care by 417.8% in the 1st quarter. Brooklyn Investment Group now owns 3,397 shares of the medical device company's stock valued at $65,000 after purchasing an additional 2,741 shares during the period. Nisa Investment Advisors LLC lifted its stake in shares of Tandem Diabetes Care by 186.9% in the 2nd quarter. Nisa Investment Advisors LLC now owns 4,171 shares of the medical device company's stock valued at $78,000 after purchasing an additional 2,717 shares during the period. Finally, State of Wyoming lifted its stake in shares of Tandem Diabetes Care by 49.1% in the 1st quarter. State of Wyoming now owns 4,467 shares of the medical device company's stock valued at $86,000 after purchasing an additional 1,471 shares during the period.</p>
<div class="lb-trans"><p>一些對沖基金和其他機構投資者最近對 TNDM 的持倉進行了調整。Assetmark Inc.在第一季度將其在 Tandem Diabetes Care 的股份增加了 42.9%。Assetmark Inc.目前持有 1,750 股該醫療設備公司的股票，價值 34,000 美元，此前在該期間內購買了 525 股。CWM LLC 在第二季度將其在 Tandem Diabetes Care 的股份增加了 262.6%。CWM LLC 目前持有 2,796 股該醫療設備公司的股票，價值 52,000 美元，此前在該期間內購買了 2,025 股。布魯克林投資集團在第一季度將其在 Tandem Diabetes Care 的股份增加了 417.8%。布魯克林投資集團目前持有 3,397 股該醫療設備公司的股票，價值 65,000 美元，此前在該期間內購買了 2,741 股。Nisa Investment Advisors LLC 在第二季度將其在 Tandem Diabetes Care 的股份增加了 186.9%。Nisa Investment Advisors LLC 目前持有 4,171 股該醫療設備公司的股票，價值 78,000 美元，此前在該期間內購買了 2,717 股。最後，懷俄明州在第一季度將其在 Tandem Diabetes Care 的股份增加了 49.1%。懷俄明州目前持有 4,467 股該醫療設備公司的股票，價值 86,000 美元，此前在該期間內購買了 1,471 股。</p>
</div><h2>Tandem Diabetes Care Company Profile</h2>
<div class="lb-trans"><h2>Tandem Diabetes Care 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.</p>
<div class="lb-trans"><p>Tandem Diabetes Care, Inc.是一家醫療設備公司，設計、開發和商業化技術解決方案，服務於美國及國際上的糖尿病患者。該公司的旗艦產品是 t:slim X2 胰島素輸送系統，這是一個用於管理胰島素輸送並在泵的主屏幕上直接顯示連續血糖監測傳感器信息的泵平台；以及 Tandem Mobi 胰島素泵，這是一個自動胰島素輸送系統。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另見</h2>
</div><ul>
<li>Five stocks we like better than Tandem Diabetes Care</li>
<li>What Do S&amp;P 500 Stocks Tell Investors About the Market?</li>
<li>This AI Chip Giant Could Be the Market’s Next Big Winner</li>
<li>How to Calculate Retirement Income: MarketBeat’s Calculator</li>
<li>Broadcom Inks OpenAI Deal: Why It's A Huge Win for AVGO Stock</li>
<li>3 Grocery Stocks That Are Proving They Are Still Essential</li>
<li>Institutions Are Fueling CrowdStrike’s Next Leg Higher</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，勝過 Tandem Diabetes Care</li>
<li>標普 500 指數股票向投資者傳達了什麼市場信息？</li>
<li>這家 AI 芯片巨頭可能是市場下一個大贏家</li>
<li>如何計算退休收入：MarketBeat 的計算器</li>
<li>博通與 OpenAI 達成協議：這對 AVGO 股票來説是一個巨大的勝利</li>
<li>3 只超市股票證明它們仍然是必需品</li>
<li>機構正在推動 CrowdStrike 的下一輪上漲</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VE5ETQ" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NASDAQ&amp;Symbol=TNDM"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Tandem Diabetes Care Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資$1,000 在 Tandem Diabetes Care 嗎？</h2>
</div><p>Before you consider Tandem Diabetes Care, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 Tandem Diabetes Care 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tandem Diabetes Care wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Tandem Diabetes Care 並不在名單上。</p>
</div><p>While Tandem Diabetes Care currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Tandem Diabetes Care 目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Tandem Diabetes Care（納斯達克股票代碼：TNDM）的評級在 Wall Street Zen 被上調至持有